ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378
Ru
En

Hyperandrogenic Disorders and Female Diseases: Differential Diagnosis and Treatment Approaches

DOI:10.31550/1727-2378-2018-150-6-49-55
Bibliography link: Ilovaiskaya I. A. Hyperandrogenic Disorders and Female Diseases: Differential Diagnosis and Treatment Approaches. Doctor.Ru. 2018. 6(150): 49–55.
Hyperandrogenic Disorders and Female Diseases: Differential Diagnosis and Treatment Approaches
10 September 12:46

Objective of the Study: To discuss the diagnosis and differential diagnosis of hyperandrogenic disorders, and treatment approaches for these conditions.

Key Points: Hyperandrogenemia is a common endocrine disorder. The main clinical markers of hyperandrogenemia are skin problems (hirsutism, acne, and alopecia) and menstrual disturbances (hypomenorrhea). The condition may also, however, be accompanied by abdominal obesity and other manifestations. Hyperandrogenemia is most often caused by polycystic ovary syndrome (PCOS). PCOS is, however, a diagnosis of elimination, i.e., other endocrine disorders that may be accompanied by menstrual disturbances and hyperandrogenemia must be ruled out. Among them are non-classic congenital dysfunction of the adrenal cortex, hyperprolactinemia, hypothyroidism, and such less common conditions as androgen-secreting tumors, HAIR-AN syndrome, hypercorticism, and acromegaly.

Conclusion: Confirmation of biochemical hyperandrogenemia is not the final step, but the starting point of medical examination. When hyperandrogenemia is detected, differential diagnosis should be done to search for its causes. Combined oral contraceptives often become an important component of a treatment plan for PCOS, non-classic congenital dysfunction of the adrenal cortex, and some other conditions accompanied by hyperandrogenemia.


I. A. Ilovaiskaya — M. F. Vladimirsky Moscow Regional Clinical Research Institute. E-mail: irena.ilov@yandex.ru

Hyperandrogenic Disorders and Female Diseases: Differential Diagnosis and Treatment Approaches
10 September 12:46
LITERATURE
  1. Melmed S., Polonsky K. S., Larsen P. R., Kronenberg H. M., eds. Williams Textbook of Endocrinology. N.Y.: Elsevier; 2016. 1936 p.
  2. Martin K. A., Anderson R. R., Chang R. J., Ehrmann D. A., Lobo R. A., Murad M. H. et al. Evaluation and treatment of hirsutism in pre­menopausal women: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2018. [Epub. ahead of print]. DOI: 10.1210/jc.2018­00241
  3. Савельева Г. М., Сухих Г. Т., Серов В. Н., Радзинский В. Е., Манухин И. Б., ред. Гинекология. Национальное руководство. М.: ГЭОТАР­Медиа; 2017. 1008 с. [Savel'eva G. M., Sukhikh G. T., Serov V. N., Radzinskii V. E., Manukhin I. B., red. Ginekologiya. Natsional'noe rukovodstvo. M.: GEOTAR­Media; 2017. 1008 s. (in Russian)]
  4. Escobar­Morreale H. F., Carmina E., Dewailly D., Gambineri A., Kelestimur F., Moghetti P. et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum. Reprod. Update. 2012; 18(2): 146–70. DOI: 10.1093/humupd/dmr042
  5. Gabrielli L., Aquino E. M. Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Reprod. Biol. Endocrinol. 2012; 10: 96. DOI: 10.1186/1477­7827­10­96
  6. March W. A., Moore V. M., Willson K. J., Phillips D. I., Norman R. J., Davies M. J. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 2010; 25(2): 544–51. DOI: 10.1093/humrep/dep399
  7. Sanchón R., Gambineri A., Alpañés M., Martínez­García M. Á., Pasquali R., Escobar­Morreale H. F. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Hum. Reprod. 2012; 27(4): 1209–16. DOI: 10.1093/humrep/des028
  8. Legro R. S., Arslanian S. A., Ehrmann D. A., Hoeger K. M., Murad M. H., Pasquali R. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013; 98(12): 4565–92. DOI: 10.1210/jc.2013­2350
  9. Дедов И. И., Мельниченко Г. А., ред. Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ. М.: Литтерра; 2013. 1024 с. [Dedov I. I., Mel'nichenko G. A., red. Ratsional'naya farmakoterapiya zabolevanii endokrinnoi sistemy i narushenii obmena veshchestv. M.: Litterra; 2013. 1024 s. (in Russian)]
  10. Дедов И. И., Мельниченко Г. А., ред. Эндокринология. Национальное руководство. М.: ГЕОТАР­Медиа; 2016. 1142 с. [Dedov I. I., Mel'nichenko G. A., red. Endokrinologiya. Natsional'noe rukovodstvo. M.: GEOTAR­Media; 2016. 1142 s. (in Russian)]
  11. Yildiz B. O., Bolour S., Woods K., Moore A., Azziz R. Visually scoring hirsutism. Hum. Reprod. Update. 2010; 16(1): 51–64. DOI: 10.1093/humupd/dmp024
  12. DeUgarte C. M., Woods K. S., Bartolucci A. A., Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J. Clin. Endocrinol. Metab. 2006; 91(4): 1345–50.
  13. Cheewadhanaraks S., Peeyananjarassri K., Choksuchat C. Clinical diagnosis of hirsutism in Thai women. J. Med. Assoc. Thai. 2004; 87(5): 459–63.
  14. Zargar A. H., Wani A. I., Masoodi S. R., Laway B. A., Bashir M. I., Salahuddin M. Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent. Fertil. Steril. 2002; 77(4): 674–8.
  15. Wild R. A., Carmina E., Diamanti­Kandarakis E., Dokras A., Escobar­Morreale H. F., Futterweit W. et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE­PCOS) Society. J. Clin. Endocrinol. Metab. 2010; 95: 2038–49. DOI: 10.1210/jc.2009­2724
  16. Адамян Л. В., Андреева Е. Н., Гаспарян С. А., Геворкян М. А., Григо­рян О. Р., Гринева Е. Н. и др. Синдром поликистозных яичников в репродуктивном возрасте (современные подходы к диагностике и лечению). Клинические рекомендации (протокол лечения). М.; 2015. 22 с. [Adamyan L. V., Andreeva E. N., Gasparyan S. A., Gevorkyan M. A., Grigoryan O. R., Grineva E. N. i dr. Sindrom polikistoznykh yaichnikov v reproduktivnom vozraste (sovremennye podkhody k diagnostike i lecheniyu). Klinicheskie rekomendatsii (protokol lecheniya). M.; 2015. 22 s. (in Russian)]
  17. Azziz R., Carmina E., Dewailly D., Diamanti­Kandarakis E., Escobar­Morreale H. F., Futterweit W. et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 2006; 91: 4237–45. DOI: 10.1210/jc.2006­0178
  18. Azziz R., Carmina E., Dewailly D., Diamanti­Kandarakis E., Escobar­Morreale H. F., Futterweit W. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 2009; 91(2): 456–88. DOI: 10.1016/j.fertnstert.2008.06.035
  19. Молашенко Н. В., Сазонова А. И., Трошина Е. А. Диагностика и лечебно­профилактические мероприятия при врожденной дисфункции коры надпочечников вследствие дефицита 21­гидроксилазы у пациентов во взрослом возрасте. Арх. акушерства и гинекологии им. В. Ф. Снегирева. 2016; 3(1): 26–32. [Molashenko N. V., Sazonova A. I., Troshina E. A. Diagnostika i lechebno­profilakticheskie meropriyatiya pri vrozhdennoi disfunktsii kory nadpochechnikov vsledstvie defitsita 21­gidroksilazy u patsientov vo vzroslom vozraste. Arkh. akusherstva i ginekologii im. V. F. Snegireva. 2016; 3(1): 26–32. (in Russian)] DOI: 10.18821/2313­8726­2016­3­1­26­32
  20. Speiser P. W., Azziz R., Baskin L. S., Ghizzoni L., Hensle T. W., Merke D. P. et al. Congenital adrenal hyperplasia due to steroid 21­hydroxylase deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2010; 95(9): 4133–60. DOI: 10.1210/jc.2009­2631
  21. Rager K. M., Omar H. A. Androgen excess disorders in women: the severe insulin­resistant hyperandrogenic syndrome, HAIR­AN. Sci. World J. 2006; 6: 116–21. DOI: 10.1100/tsw.2006.23
  22. Tong A., Jiang J., Wang F., Li C., Zhang Y., Wu X. Pure androgen­producing adrenal tumor: clinical features and pathogenesis. Endocr. Pract. 2017; 23(4): 399–407. DOI: 10.4158/EP161580.OR
  23. Katznelson L., Laws E. R. Jr., Melmed S., Molitch M. E., Murad M. H., Utz A. et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014; 99(11): 3933–51. DOI: 10.1210/jc.2014­2700
  24. Дедов И. И., Мельниченко Г. А., ред. Федеральные клинические рекомендации по акромегалии: клиника, диагностика, дифференциальная диагностика и методы лечения. М.; 2015. 35 с. [Dedov I. I., Mel'nichenko G. A., red. Federal'nye klinicheskie rekomendatsii po akromegalii: klinika, diagnostika, differentsial'naya diagnostika i metody lecheniya. M.; 2015. 35 s. (in Russian)]
  25. Debono M., Newell­Price J. D. Cushing's syndrome: where and how to find it. Front. Horm. Res. 2016; 46: 15–27. DOI: 10.1159/000443861
  26. Livadas S., Dracopoulou M., Dastamani A., Sertedaki A., Maniati­Christidi M., Magiakou A. M. et al. The spectrum of clinical, hormonal and molecular findings in 280 individual with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene. Clin. Endocrinol. (Oxf). 2015; 82(4): 543–9. DOI: 10.1111/cen.12543
  27. Conway G., Dewailly D., Diamanti­Kandarakis E., Escobar­Morreale H. F., Franks S., Gambineri A. et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 2014; 171(4): P1–29. DOI: 10.1530/EJE­14­0253
  28. Lizneva D., Gavrilova­Jordan L., Walker W., Azziz R. Androgen excess: Investigations and management. Best Pract. Res. Clin. Obstet. Gynaecol. 2016; 37: 98–118. DOI: 10.1016/j.bpobgyn.2016.05.003
  29. Moal V., Mathieu E., Reynier P., Malthièry Y., Gallois Y. Low serum testosterone assayed by liquid chromatography­tandem mass spectrometry. Comparison with five immunoassay techniques. Clin. Chim. Acta. 2007; 386(1–2): 12–19. DOI:10.1016/j.cca.2007.07.013
  30. Pugeat M., Plotton I., Brac de la Perrière A., Raverot G., Déchaud H., Raverot V. Management of endocrine disease hyperandrogenic states in women: pitfalls in laboratory diagnosis. Eur. J Endocrinol. 2018; 178(4): R141–54. DOI: 10.1530/EJE­17­0776
  31. Janse F., Eijkemans M. J., Goverde A. J., Lentjes E. G., Hoek A , Lambalk C B. et al. Assessment of androgen concentration in women: liquid chromatography­tandem mass spectrometry and extraction RIA show comparable results. Eur. J. Endocrinol. 2011; 165(6): 925–33. DOI: 10.1530/EJE­11­0482
  32. Goodman N. F., Cobin R. H., Futterweit W., Glueck J. S., Legro R. S., Carmina E.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome — part 1. Endocr. Pract. 2015; 21(11): 1291–300. DOI: 10.4158/EP15748.DSC
  33. Goodman N. F., Cobin R. H., Futterweit W., Glueck J. S., Legro R. S., Carmina E.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American ASSOCIATION of Clinical Endocrinologists, American College of Endocrinology, and ANDROGEN EXCESS and PCOS SOCIETY disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome — part 2. Endocr. Pract. 2015; 21(12): 1415–26. DOI: 10.4158/EP15748.DSCPT2
  34. Ly L. P., Handelsman D. J. Empirical estimation of free testosterone from testosterone and sex hormone­binding globulin immunoassays. Eur. J. Endocrinol. 2005; 152(3): 471–8. DOI: 10.1530/eje.1.01844
  35. Christodoulaki C., Trakakis E., Pergialiotis V., Panagopoulos P., Chrelias C., Kassanos D. et al. Dehydroepiandrosterone­sulfate, insulin resistance and ovarian volume estimation in patients with polycystic ovarian syndrome. J. Fam. Reprod. Health. 2017; 11(1): 24–9.
  36. Lerchbaum E., Schwetz V., Rabe T., Giuliani A., Obermayer­Pietsch B. Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype. PLoS One. 2014; 9(10): e108263. DOI: 10.1371/journal.pone.0108263
  37. O'Reilly M. W., Taylor A. E., Crabtree N. J., Hughes B. A., Capper F., Crowley R. K. et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J. Clin. Endocrinol. Metab. 2014; 99(3): 1027–36. DOI: 10.1210/jc.2013­3399
  38. Дедов И. И., Мельниченко Г. А., ред. Федеральные клинические рекомендации по гиперпролактинемии: клиника, диагностика, дифференциальная диагностика и методы лечения. М.; 2015. 19 с. [Dedov I. I., Mel'nichenko G. A., red. Federal'nye klinicheskie rekomendatsii po giperprolaktinemii: klinika, diagnostika, differentsial'naya diagnostika i metody lecheniya. M.; 2015. 19 s. (in Russian)]
  39. van Zuuren E. J., Fedorowicz Z., Carter B., Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst. Rev. 2015; 4: CD010334. DOI: 10.1002/14651858.CD010334.pub2
  40. Saito K., Ando H., Goto K., Kakuma T., Kawano Y., Narahara H. et al. A case of hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome; increase in proliferating cell nuclear antigen and decrease in loricrin in acanthosis nigricans. Ann. Dermatol. 2016; 28(5): 637–9.
  41. Regidor P. A., Schindler A. E. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone. Oncotarget. 2017;8(47): 83334–42. DOI: 10.18632/oncotarget.19833
  42. Li J., Ren J., Sun W. A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 210: 13–21. DOI: 10.1016/j.ejogrb.2016.11.013
  43. Dinger J., Bardenheuer K., Heinemann K. Cardiovascular and general safety of a 24­day regimen of drospirenone­containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014; 89(4): 253–63. DOI: 10.1016/j.contraception.2014.01.023
Similar article
19 May 15:04, Allergology
V.M. Ganuzin, N.L. Chernaya, G.S. Maskova
Features of Specialised Medical Consultation of Adolescents with Bronchial Asthma: Clinical Observation
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)
19 May 14:30, Allergology
S.E. Mitskevich, I.A. Fedorov, A.I. Chuprynina, O.G. Rybakova
Use of Omalizumab in Management of Severe Uncontrolled Bronchial Asthma in Children
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)

Partners